Health
Authors
News Type
News
Date
Paragraphs

Stanley Perlman, who has been studying coronaviruses for 39 years, got a nasty email June 4: “Dr. Frankenstein just wants more public money and wants to research things he shouldn’t be messing with. THANKS A LOT FOR CORONA LOSER.”

Perlman, a mild-mannered, grandfatherly virologist at the University of Iowa, didn’t know the author of the dyspeptic email and had nothing to do with the emergence of the coronavirus. But he had co-signed a letter to the Lancet in February 2020 saying SARS-CoV-2 was not a bioengineered virus and condemning “conspiracy theories suggesting that COVID-19 does not have a natural origin.”

Read the rest at The Washington Post

Hero Image
Man smiling
All News button
1
Subtitle

Stanford University microbiologist David A. Relman said the political climate last year made many scientists hesitant to express openness to the lab-leak idea. They did not want to align themselves with a theory closely associated with Trump and his allies, who referred to the coronavirus as “the China virus.”

Authors
News Type
Commentary
Date
Paragraphs

This interview by Bruce Goldman was originally published by the Stanford School of Medicine.


On May 13, the journal Science published a letter, signed by 18 scientists, stating that it was still unclear whether the virus that causes COVID-19 emerged naturally or was the result of a laboratory accident, but that neither cause could be ruled out. David Relman, MD, the Thomas C. and Joan M. Merigan Professor and professor of microbiology and immunology, spearheaded the effort.

Relman is no stranger to complicated microbial threat scenarios and illness of unclear origin. He has advised the U.S. government on emerging infectious diseases and potential biological threats. He served as vice chair of a National Academy of Sciences committee reviewing the FBI investigation of letters containing anthrax that were sent in 2001. Recently, he chaired another academy committee that assessed a cluster of poorly explained illnesses in U.S. embassy employees. He is a past president of the Infectious Diseases Society of America.

Stanford Medicine science writer Bruce Goldman asked Relman to explain what remains unknown about the coronavirus’s emergence, what we may learn and what’s at stake.

1. How might SARS-CoV-2, which causes COVID-19, have first infected humans?

Relman: We know very little about its origins. The virus’s closest known relatives were discovered in bats in Yunnan Province, China, yet the first known cases of COVID-19 were detected in Wuhan, about 1,000 miles away.

There are two general scenarios by which this virus could have made the jump to humans. First, the jump, or “spillover,” might have happened directly from an animal to a human, by means of an encounter that took place within, say, a bat-inhabited cave or mine, or closer to human dwellings — say, at an animal market. Or it could have happened indirectly, through a human encounter with some other animal to which the primary host, presumably a bat, had transmitted the virus.

Bats and other potential SARS-CoV-2 hosts are known to be shipped across China, including to Wuhan. But if there were any infected animals near or in Wuhan, they haven’t been publicly identified.

Maybe someone became infected after contact with an infected animal in or near Yunnan, and moved on to Wuhan. But then, because of the high transmissibility of this virus, you’d have expected to see other infected people at or near the site of this initial encounter, whether through similar animal exposure or because of transmission from this person.

2. What’s the other scenario?

Relman: SARS-CoV-2 could have spent some time in a laboratory before encountering humans. We know that some of the largest collections of bat coronaviruses in the world — and a vigorous research program involving the creation of “chimeric” bat coronaviruses by integrating unfamiliar coronavirus genomic sequences into other, known coronaviruses — are located in downtown Wuhan. And we know that laboratory accidents happen everywhere there are laboratories.

Humans are fallible, and laboratory accidents happen — far more often than we care to admit.
David Relman
Senior Fellow, CISAC

All scientists need to acknowledge a simple fact: Humans are fallible, and laboratory accidents happen — far more often than we care to admit. Several years ago, an investigative reporter uncovered evidence of hundreds of lab accidents across the United States involving dangerous, disease-causing microbes in academic institutions and government centers of excellence alike — including the Centers for Disease Control and Prevention and the National Institutes of Health.

SARS-CoV-2 might have been lurking in a sample collected from a bat or other infected animal, brought to a laboratory, perhaps stored in a freezer, then propagated in the laboratory as part of an effort to resurrect and study bat-associated viruses. The materials might have been discarded as a failed experiment. Or SARS-CoV-2 could have been created through commonly used laboratory techniques to study novel viruses, starting with closely related coronaviruses that have not yet been revealed to the public. Either way, SARS-CoV-2 could have easily infected an unsuspecting lab worker and then caused a mild or asymptomatic infection that was carried out of the laboratory.

3. Why is it important to understand SARS-CoV-2’s origins?

Relman: Some argue that we would be best served by focusing on countering the dire impacts of the pandemic and not diverting resources to ascertaining its origins. I agree that addressing the pandemic’s calamitous effects deserves high priority. But it’s possible and important for us to pursue both. Greater clarity about the origins will help guide efforts to prevent a next pandemic. Such prevention efforts would look very different depending on which of these scenarios proves to be the most likely.

Evidence favoring a natural spillover should prompt a wide variety of measures to minimize human contact with high-risk animal hosts. Evidence favoring a laboratory spillover should prompt intensified review and oversight of high-risk laboratory work and should strengthen efforts to improve laboratory safety. Both kinds of risk-mitigation efforts will be resource intensive, so it’s worth knowing which scenario is most likely.

4. What attempts at investigating SARS-CoV-2’s origin have been made so far, with what outcomes?

Relman: There’s a glaring paucity of data. The SARS-CoV-2 genome sequence, and those of a handful of not-so-closely-related bat coronaviruses, have been analyzed ad nauseam. But the near ancestors of SARS-CoV-2 remain missing in action. Absent that knowledge, it’s impossible to discern the origins of this virus from its genome sequence alone. SARS-CoV-2 hasn’t been reliably detected anywhere prior to the first reported cases of disease in humans in Wuhan at the end of 2019. The whole enterprise has been made even more difficult by the Chinese national authorities’ efforts to control and limit the release of public health records and data pertaining to laboratory research on coronaviruses.

In mid-2020, the World Health Organization organized an investigation into the origins of COVID-19, resulting in a fact-finding trip to Wuhan in January 2021. But the terms of reference laying out the purposes and structure of the visit made no mention of a possible laboratory-based scenario. Each investigating team member had to be individually approved by the Chinese government. And much of the data the investigators got to see was selected prior to the visit and aggregated and presented to the team by their hosts.

The recently released final report from the WHO concluded — despite the absence of dispositive evidence for either scenario — that a natural origin was “likely to very likely” and a laboratory accident “extremely unlikely.” The report dedicated only 4 of its 313 pages to the possibility of a laboratory scenario, much of it under a header entitled “conspiracy theories.” Multiple statements by one of the investigators lambasted any discussion of a laboratory origin as the work of dark conspiracy theorists. (Notably, that investigator — the only American selected to be on the team — has a pronounced conflict of interest.)

Given all this, it’s tough to give this WHO report much credibility. Its lack of objectivity and its failure to follow basic principles of scientific investigation are troubling. Fortunately, WHO’s director-general recognizes some of the shortcomings of the WHO effort and has called for a more robust investigation, as have the governments of the United States, 13 other countries and the European Union.

5. What’s key to an effective investigation of the virus’s origins?

Relman: A credible investigation should address all plausible scenarios in a deliberate manner, involve a wide variety of expertise and disciplines and follow the evidence. In order to critically evaluate other scientists’ conclusions, we must demand their original primary data and the exact methods they used — regardless of how we feel about the topic or about those whose conclusions we seek to assess. Prior assumptions or beliefs, in the absence of supporting evidence, must be set aside.

Investigators should not have any significant conflicts of interest in the outcome of the investigation, such as standing to gain or lose anything of value should the evidence point to any particular scenario.

There are myriad possible sources of valuable data and information, some of them still preserved and protected, that could make greater clarity about the origins feasible. For all of these forms of data and information, one needs proof of place and time of origin, and proof of provenance.

To understand the place and time of the first human cases, we need original records from clinical care facilities and public health institutions as well as archived clinical laboratory data and leftover clinical samples on which new analyses can be performed. One might expect to find samples of wildlife, records of animal die-offs and supply-chain documents.

Efforts to explore possible laboratory origins will require that all laboratories known to be working on coronaviruses, or collecting relevant animal or clinical samples, provide original records of experimental work, internal communications, all forms of data — especially all genetic-sequence data — and all viruses, both natural and recombinant. One might expect to find archived sequence databases and laboratory records.

Needless to say, the politicized nature of the origins issue will make a proper investigation very difficult to pull off. But this doesn’t mean that we shouldn’t try our best. Scientists are inquisitive, capable, clever, determined when motivated, and inclined to share their insights and findings. This should not be a finger-pointing exercise, nor an indictment of one country or an abdication of the important mission to discover biological threats in nature before they cause harm. Scientists are also committed to the pursuit of truth and knowledge. If we have the will, we can and will learn much more about where and how this pandemic arose.  

relman

David Relman

Senior Fellow at the Freeman Spogli Institute for International Studies
Full Profile

Read More

Two bats hanging upside down
News

Bat-borne Nipah virus could help explain COVID-19

Researchers have long known that the number of human infections from the bat-borne Nipah virus fluctuates from year to year. A new study provides insights into the reasons why. Stanford epidemiologist Stephen Luby, MD, discussed the findings and how they relate to COVID-19.
Bat-borne Nipah virus could help explain COVID-19
People in suits burying a body
Commentary

To stop the next pandemic, we need to unravel the origins of COVID-19

We find ourselves ten months into one of the most catastrophic global health events of our lifetime and we still do not know how it began. Despite the critical importance of this question, efforts to investigate the origins have become mired in politics, poorly supported assumptions and assertions, and incomplete information.
To stop the next pandemic, we need to unravel the origins of COVID-19
Bat hanging from a branch
Q&As

Viral lessons: What a little-known virus could teach us about COVID-19

Stanford epidemiologist Stephen Luby discusses surprising results of a recent study on Nipah virus, a disease with no vaccine and a mortality rate of up to 70 percent.
Viral lessons: What a little-known virus could teach us about COVID-19
Hero Image
Researchers examine medical vials Getty Images
All News button
1
Subtitle

Microbiologist David Relman discusses the importance of understanding how the coronavirus emerged.

-

Peter ("Pete") W. Groeneveld, MD, MS is Professor of Medicine at the University of Pennsylvania’s Perelman School of Medicine and a primary care physician at Philadelphia’s Corporal Michael J. Crescenz VA Medical Center. He is the Founding Director of Penn’s Cardiovascular Outcomes, Quality, and Evaluative Research (CAVOQER) Center, Director of Research at Penn’s Leonard Davis Institute of Health Economics (LDI), Chair of the VA’s Research and Development Committee, Co-Director of Penn’s Master of Science in Health Policy (MSHP) program, and Associate Director of the VA’s Center for Health Equity Research and Promotion. Dr. Groeneveld’s research is focused on the quality, outcomes, costs, and equity of high-technology cardiovascular care, and his methodological expertise is in the analysis of a wide variety of health care data, including administrative claims, clinical registries, electronic medical records, and surveys. His research has been funded by the VA, NIH, AHRQ, and the Commonwealth of Pennsylvania, and he has co-authored over 100 peer-reviewed publications. Dr. Groeneveld is a Fellow of the American Heart Association and of the American College of Physicians, and he is an elected member of the American Society for Clinical Investigation (ASCI).

Title: Cardiology Physician Group Practice Vertical Integration and the Use of Cardiovascular Imaging

Abstract: A substantial proportion of previously independent U.S. cardiology physician practices have become vertically integrated into larger health systems.  It is unclear if vertical integration affected the clinical practice patterns of these cardiologists.  Longitudinal data from cardiology practice surveys from 2008-2013 were combined with Medicare fee-for-service claims for two common cardiology imaging tests: echocardiograms and cardiac nuclear studies. Cardiologists who transitioned from independent to hospital- or health system-owned practices ordered 17% more echocardiograms and 10% more cardiac nuclear imaging studies after their practices had transitioned.  Our findings surprisingly suggest that vertical integration of cardiologists' practices was associated with higher rates of cardiovascular imaging.  Potential explanations include preferential integration of group practices with lower pre-integration imaging rates, increased post-integration clinician incentives for ordering tests, and/or reduced administrative barriers to obtaining testing after integration. 

Zoom Meeting

Register in advance for this meeting:
https://stanford.zoom.us/meeting/register/tJwqduivrDMrEtDKYMqYvz3A_hVwRSE0_-A6 

After registering, you will receive a confirmation email containing information about joining the meeting.

Peter W. Groeneveld, MD, MS
All Publications button
1
Publication Type
Journal Articles
Publication Date
Subtitle
Now that a third COVID-19 vaccine has been given emergency-use authorization, Michelle Mello and colleagues ask whether individuals should be able to choose which vaccine they receive.
Journal Publisher
The New England Journal of Medicine
Authors
Michelle Mello
-

Pascal Geldsetzer, PhD 
Assistant Professor of Medicine in the Division of Primary Care and Population Health

Title:  Regression Discontinuity in Electronic Health Record Data

Abstract: Regression discontinuity in electronic health record (EHR) data combines the main advantage of randomized controlled trials (causal inference without needing to adjust for confounders) with the large size, low cost, and representativeness of observational studies in routinely collected medical data. Regression discontinuity could be an important tool to help clinical medicine move away from a “one size fits all” approach because, along with the increasing size and availability of EHR data, it would allow for a rigorous examination of how treatment effects vary across highly granular patient subgroups. In addition, given the broad range of health outcomes recorded in EHR data, this design could be used to systematically test for a wide range of unexpected beneficial and adverse health effects of different treatments. I will talk about the broad motivation for this research and discuss examples from some of our ongoing work in this area. If there is time, I will also discuss some of my ongoing research on improving healthcare services for chronic conditions in low- and middle-income country settings. 

Zoom Meeting

Register in advance for this meeting:
https://stanford.zoom.us/meeting/register/tJYpcO2ppzooGNdbf8o1OxXNUWd3rukNEb7i 

After registering, you will receive a confirmation email containing information about joining the meeting.

-

Alyce S. Adams, PhD 
Professor of Medicine, Stanford's Center for Health Policy & Center for Primary Care and Outcomes Research
Professor of Epidemiology and Population Health in the Stanford School of Medicine 
Associate Director for Health Equity and Community Engagement in the Stanford Cancer Institute 

Title: Health Policy and the Fight for Equitable Healthcare Outcomes: Why Access Isn’t Enough

Abstract: Using evidence from evaluations of natural experiments, Alyce Adams will discuss the intended and unintended consequences of changes in prescription drug policy at the state and federal level of low income and minority individuals with multiple chronic conditions. We will explore the potential for policy effects to have an immediate and dramatic increase in access to clinically essential treatments. However, she will also discuss where such policies can widen, rather than reduce disparities in treatment. We concluded that increasing access (while critical) is not sufficient to address inequities in treatment use and outcomes among high risk populations. Importantly, new strategies are needed to inform the design of policy interventions that promote access, while simultaneously advancing health equity.

Register in advance for this meeting:
https://stanford.zoom.us/meeting/register/tJcsf-6pqDwtH93u_yfFbEkV_XIbJ2gai0FV  

After registering, you will receive a confirmation email containing information about joining the meeting.

0
Stanford Medicine Innovation Professor
alyce_profile_2022.jpg PhD, MPP

Alyce Adams is the inaugural Stanford Medicine Innovation Professor and Professor of Health Policy, Epidemiology and Population Health and of Pediatrics (by Courtesy). She also serves as Associate Chair for Community Outreach and Engagement for Stanford Health Policy, and as Associate Director for Partnership and Community Engagement in the Stanford Cancer Institute. Focusing on pharmaceutical treatments for cancer and diabetes, Dr. Adams' research evaluates health system and policy level interventions to improve access, balance the benefits and harms of treatment, improve patient-valued outcomes, and reduce disparities.

Professor, Epidemiology and Population Health
Professor, Health Policy
Professor, Pediatrics (by courtesy)
CV
Date Label
News Type
News
Date
Paragraphs

Foreign Policy: China Will Run Out of Growth if it Doesn't Fix its Rural Crisis

No country with China’s vast education and public health problems has ever broken out of the ranks of middle-income countries.

"At a time when every other major economy is shrinking, China announced in late January that its GDP grew 2.3 percent in 2020. Beneath that impressive achievement, however, lies a very unbalanced recovery: As in the past, Beijing relied heavily on state investment and a state-led push for higher industrial production, while private investment and consumer spending remained weak. Easy credit to fuel growth has likely formed even more so-called zombie companies with little prospect of future profitability and filled the books of Chinese banks with even more bad loans.

That much is familiar to many who have taken a closer look at China’s skewed model for economic growth. What’s much less well known is the disproportionate burden of the COVID-19-induced downturn that has fallen on rural Chinese, including the 290 million migrant workers with rural hukou (household registrations) who work in cities throughout China. Lockdowns forced by the pandemic paralyzed economic sectors where many migrants work, such as services and retail. According to one estimate, Chinese migrant workers lost about $100 billion in wages that they are unlikely ever to recover.

Among migrant workers and the underdeveloped rural communities that depend on the wages they send home, a quiet crisis is taking place—with potentially dramatic consequences for China’s future growth. Despite what the GDP number suggests about the country’s successful handling of the pandemic, China’s longer-term economic risks have only grown—and are a direct result of the crisis in rural China. As Stanford University researchers Scott Rozelle and Natalie Hell document in their meticulously researched book, Invisible China: How the Urban-Rural Divide Threatens China’s Risehundreds of millions of rural Chinese face a dangerous lack of human capital and suffer from pervasive health problems, including widespread iron-deficiency anemia, uncorrected myopia, and parasitic intestinal worms. Exacerbated by the pandemic, China’s rural crisis remains largely invisible to outside observers, and even to many Chinese."

 

Read the full article from Foreign Policy.

Hero Image
A mother and child preparing food inside a yurt in rural China. GettyImages - Matteo Colombo
All News button
1
Subtitle

Chorzempa & Huang write on China's rural human capital crisis stating that "no country with China's vast education and public health problems has ever broken out of the ranks of middle-income countries." The article references FSI Senior Fellow and SCCEI Director Scott Rozelle's book "Invisible China: How the Urban-Rural Divide Threatens China’s Rise" throughout.

Subscribe to Health